Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes FX006, a sustained-release intra-articular steroid, which has completed a Phase IIb dose-ranging clinical trial to treat moderate to severe osteoarthritis (OA) pain. The company is also developing FX007, a preclinical, small-molecule TrkA receptor antagonist to address post-operative pain; and FX005, a sustained-release intra-articular p38 MAP kinase inhibitor, which has completed a Phase IIa clinical trial intended as a therapy for patients with end-stage OA pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-21.24%||ROE||-21.88%||ROI|
|Current Ratio||32.27||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.03|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||-3.69 M||Cash From Investing Activities||-62.47 M||Cash From Operating Activities||-9.98 M||Gross Profit|
|Net Profit||-9.17 M||Operating Profit||-9.01 M||Total Assets||141.02 M||Total Current Assets||134.24 M|
|Total Current Liabilities||4.16 M||Total Debt||Total Liabilities||4.19 M||Total Revenue|
|High 52 week||19.6||Low 52 week||9.07||Last close||14.15||Last change||2.39%|
|RSI||43.06||Average true range||0.79||Beta||1.41||Volume||629.96 K|
|Simple moving average 20 days||1.12%||Simple moving average 50 days||9.85%||Simple moving average 200 days||14.99%|
|Performance Week||4.12%||Performance Month||-2.82%||Performance Quart||28.64%||Performance Half||34%|
|Performance Year||-23.01%||Performance Year-to-date||25%||Volatility daily||2.59%||Volatility weekly||5.79%|
|Volatility monthly||11.87%||Volatility yearly||41.12%||Relative Volume||286.22%||Average Volume||623.19 K|
|New High||New Low|
2020-05-28 09:13:01 | Flexion FLXN Soars: Stock Adds 6.6% in Session
2020-05-21 12:02:00 | Why Flexion Therapeutics Is Tumbling 10% Today
2020-05-21 07:30:10 | Flexion Therapeutics Announces Pricing of Public Offering of Common Stock
2020-05-20 16:01:10 | Flexion Therapeutics Announces Proposed Public Offering of Common Stock
2020-05-14 09:27:01 | How Flexion Therapeutics FLXN Stock Stands Out in a Strong Industry
2020-05-09 15:00:34 | Flexion Therapeutics Inc FLXN Q1 2020 Earnings Call Transcript
2020-05-08 16:14:23 | Edited Transcript of FLXN earnings conference call or presentation 7-May-20 8:30pm GMT
2020-05-05 09:00:10 | Flexion Therapeutics Announces Virtual Poster Presentations for FX201, an Intra-Articular Gene Therapy Candidate for the Treatment of Osteoarthritis, at the American Society of Gene & Cell Therapy Annual Meeting
2020-04-30 16:30:10 | Flexion Therapeutics to Report First-Quarter 2020 Financial Results on May 7, 2020
2020-04-07 16:30:10 | Flexion Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
2020-04-03 16:30:10 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4
2020-03-13 01:16:43 | Edited Transcript of FLXN earnings conference call or presentation 12-Mar-20 8:30pm GMT
2020-03-12 18:35:10 | Flexion Therapeutics FLXN Reports Q4 Loss, Tops Revenue Estimates
2020-03-12 16:01:10 | Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results
2020-03-11 16:30:10 | Flexion Therapeutics Names Melissa Layman Chief Commercial Officer
2020-03-06 16:30:10 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4
2020-03-05 12:30:05 | Will Flexion Therapeutics FLXN Report Negative Earnings Next Week? What You Should Know
2020-02-20 07:12:44 | Have Insiders Been Buying Flexion Therapeutics, Inc. NASDAQ:FLXN Shares?
2020-02-07 16:30:10 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4
2020-01-28 14:36:06 | 5 'Strong Buy' Biotech Stocks to Buy for 2020
2020-01-15 06:34:45 | When Will Flexion Therapeutics, Inc. NASDAQ:FLXN Turn A Profit?
2020-01-10 07:13:12 | The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx
2020-01-03 16:30:10 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4
2020-01-01 18:00:09 | Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates
2019-12-31 09:39:02 | Is the Options Market Predicting a Spike in Flexion FLXN Stock?
2019-12-30 09:44:02 | Flexion's FLXN Stock Up on FDA Approval for Zilretta sNDA
2019-12-27 14:53:11 | Flexion Therapeutics soars on FDA label change approval
2019-12-27 10:33:25 | Flexion Analysts Say Long-Delayed Zilretta Label Expansion A Relief For Investors
2019-12-27 08:46:30 | Benzinga Pro's Top 5 Stocks To Watch For Fri., Dec. 27, 2019: NKE, AXE, PT, FLXN, ZLAB
2019-12-27 05:47:00 | Flexion Surges on FDA Label-Update Approval, Analyst Price-Target Lift
2019-12-17 07:30:10 | Flexion Therapeutics Enrolls First Patients in Phase 2 Trial of ZILRETTA® triamcinolone acetonide extended-release injectable suspension in OA of the Shoulder and Adhesive Capsulitis
2019-12-12 15:42:53 | Should You Buy Flexion Therapeutics Inc FLXN?
2019-12-12 13:12:36 | Should Investors Up the Ante on These 3 “Strong Buy” Stocks?